In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
Several CRISPR-Cas9 orthologues have been used for genome editing. Here, we present the smallest Cas9 orthologue characterized to date, derived from Campylobacter jejuni (CjCas9), for efficient genome editing in vivo . After determining protospacer-adjacent motif (PAM) sequences and optimizing single-guide RNA (sgRNA) length, we package the CjCas9 gene, its sgRNA sequence, and a marker gene in an all-in-one adeno-associated virus (AAV) vector and produce the resulting virus at a high titer. CjCas9 is highly specific, cleaving only a limited number of sites in the human or mouse genome. CjCas9, delivered via AAV, induces targeted mutations at high frequencies in mouse muscle cells or retinal pigment epithelium (RPE) cells. Furthermore, CjCas9 targeted to the Vegfa or Hif1a gene in RPE cells reduces the size of laser-induced choroidal neovascularization, suggesting that in vivo genome editing with CjCas9 is a new option for the treatment of age-related macular degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Smaller genome editing proteins, such as the S. aureus Cas9, C. jejuni Cas9 and newly identified CRISPR-Cas enzymes, may circumvent this issue 23,61-65 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The downregulation was linked to a decrease in spot size on morphology of the laser-induced choroidal neovascularization (wet AMD model) but not on retinal function measured by electroretinogram (ERG) [221].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [221]
The cited source says what the claim attributes to it.
In the citing paper
“Fonfara et al. previously reported the optimal in vitro PAM site for CjCas9 to be 5′-NNNNACA”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“In February 2017, Kim et al. presented efficient in vivo genome editing using the smallest Cas9 orthologue (2.95 kb) that has been characterized as of February 2017: Campylobacter jejuni (CjCas9) [72].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“In February 2017, Kim et al. presented efficient in vivo genome editing using the smallest Cas9 orthologue (2.95 kb) that has been characterized as of February 2017: Campylobacter jejuni (CjCas9) [72].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [72]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
Self-citationRNA-programmed genome editing in human cells
Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., & Doudna, J. (2013) · eLife · doi:10.7554/elife.00471 · Cited by 2,098
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
Self-citationStructural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease
Anders, C., Niewoehner, O., Duerst, A., & Jinek, M. (2014) · Nature · doi:10.1038/nature13579 · Cited by 1,323
Cited by
Items 101–200 of 730
Gene therapy for visual loss: Opportunities and concerns
Lee, J. H., Wang, J.-H., Chen, J., Li, F., Edwards, T. L., Hewitt, A. W., & Liu, G. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.08.003 · Cited by 107
Gene therapy for CNS disorders: modalities, delivery and translational challenges
Gao, J., Gunasekar, S., Xia, Z. J., Shalin, K., Jiang, C., Chen, H., Lee, D., Lee, S., Pisal, N. D., Luo, J. N., et al. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00829-7 · Cited by 102
Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins
Lee, J., Mir, A., Edraki, A., García, B., Amrani, N., Lou, H. E., Gainetdinov, I. V., Pawluk, A., Ibraheim, R., Gao, X. D., et al. (2018) · mBio · doi:10.1128/mbio.02321-18 · Cited by 112
Tadić, V., Josipović, G., Zoldoš, V., & Vojta, A. (2019) · Methods · doi:10.1016/j.ymeth.2019.05.003 · Cited by 107
CRISPR/Cas9 Landscape: Current State and Future Perspectives
Tyumentsev, A. I., Tyumentsev, A. I., & Акимкин, В. Г. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216077 · Cited by 112
Koo, T., Park, S. W., Jo, D. H., Kim, D., Kim, J. H., Cho, H.-Y., Kim, J. H., Kim, J. H., & Kim, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04175-y · Cited by 99
Self-citationEpigenome engineering: new technologies for precision medicine
Sgro, A., & Blancafort, P. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1000 · Cited by 99
Kemaladewi, D. U., Maino, E., Hyatt, E., Hou, H., Ding, M., Place, K. M., Zhu, X., Bassi, P. S., Baghestani, Z., Deshwar, A. G., et al. (2017) · Nature Medicine · doi:10.1038/nm.4367 · Cited by 102
CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives
Chan, Y.-T., Lu, Y., Wu, J., Zhang, C., Tan, H., Bian, Z., Wang, N., & Feng, Y. (2022) · Theranostics · doi:10.7150/thno.71144 · Cited by 104
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“The downregulation was linked to a decrease in spot size on morphology of the laser-induced choroidal neovascularization (wet AMD model) but not on retinal function measured by electroretinogram (ERG)[221].”
BackgroundInfluentialWang, Y., Liu, K. I., Sutrisnoh, N.-A. B., Srinivasan, H., Zhang, J., Li, J., Zhang, F., Richard, J. L. C., Xing, H., Shanmugam, R., et al. (2018) · Genome biology · doi:10.1186/s13059-018-1445-x · Cited by 93
Beyond Native Cas9: Manipulating Genomic Information and Function
Mitsunobu, H., Teramoto, J., Nishida, K., & Kondo, A. (2017) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.06.004 · Cited by 88
Koo, T., Lu‐Nguyen, N., Malerba, A., Kim, E., Kim, D., Cappellari, O., Cho, H., Dickson, G., Popplewell, L. J., & Kim, J. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.018 · Cited by 90
Self-citationGenome editing methods in animal models
Lee, H., Yoon, D. E., & Kim, K. (2020) · Animal Cells and Systems · doi:10.1080/19768354.2020.1726462 · Cited by 90
Self-citationExpanding the plant genome editing toolbox with recently developed CRISPR–Cas systems
Wada, N., Osakabe, K., & Osakabe, Y. (2022) · PLANT PHYSIOLOGY · doi:10.1093/plphys/kiac027 · Cited by 84
Kim, H., Choi, J., & Won, K. (2020) · BMC Plant Biology · doi:10.1186/s12870-020-02665-0 · Cited by 87
CRISPR Therapeutics for Duchenne Muscular Dystrophy
Erkut, E. J. N., & Yokota, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031832 · Cited by 96
Shen, C., Hsu, M., Chang, C.-W., Lin, M., Hwu, J. R., Tu, Y., & Hu, Y. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1165 · Cited by 86
In Vivo Genome Editing as a Therapeutic Approach
Ho, B. X., Loh, S. J. H., Chan, W., & Soh, B.-S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092721 · Cited by 82
Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges
Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J. (2019) · Genes · doi:10.3390/genes10090654 · Cited by 80
CRISPR/Cas-Based Modifications for Therapeutic Applications: A Review
Bharathkumar, N., Abraham, S., Meera, P., Aksah, S., Muthu, K., Saravanan, K. M., & Anand, T. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00422-8 · Cited by 89
CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration
Burnight, E. R., Giacalone, J. C., Cooke, J. A., Thompson, J. R., Bohrer, L. R., Chirco, K. R., Drack, A. V., Fingert, J. H., Worthington, K. S., Wiley, L. A., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.003 · Cited by 74
Advances in Nanoparticles as Non-Viral Vectors for Efficient Delivery of CRISPR/Cas9
Kim, M., Hwang, Y., Lim, S., Jang, H., & Kim, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091197 · Cited by 88
CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics
Kumar, P., Malik, Y. S., Ganesh, B., Rahangdale, S., Saurabh, S., Natesan, S. K. A., Srivastava, A., Sharun, K., Yatoo, M. I., Tiwari, R., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.576875 · Cited by 83
CRISPR/Cas9 in lepidopteran insects: Progress, application and prospects
Li, J., Shi, Y., Wu, J., Li, H., Smagghe, G. J., & Liu, T. (2021) · Journal of Insect Physiology · doi:10.1016/j.jinsphys.2021.104325 · Cited by 76
Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems
Tan, R., Krueger, R., Gramelspacher, M. J., Zhou, X., Xiao, Y., Ke, A., Hou, Z., & Zhang, Y. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.032 · Cited by 79
Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy
Lim, K. R. Q., Yoon, C., & Yokota, T. (2018) · Journal of Personalized Medicine · doi:10.3390/jpm8040038 · Cited by 81
Versatile and robust genome editing with Streptococcus thermophilus CRISPR1-Cas9
Agudelo, D., Carter, S., Velimirovic, M., Duringer, A., Rivest, J.-F., Levesque, S., Loehr, J., Mouchiroud, M., Cyr, D., Waters, P. J., et al. (2020) · Genome Research · doi:10.1101/gr.255414.119 · Cited by 85
Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
CRISPR/Cas9 gene-editing strategies in cardiovascular cells
Vermersch, E., Jouve, C., & Hulot, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz250 · Cited by 77
Virus-induced plant genome editing
Oh, Y., Kim, H., & Kim, S. (2021) · Current Opinion in Plant Biology · doi:10.1016/j.pbi.2020.101992 · Cited by 75
Self-citationEngineering Abiotic Stress Tolerance in Crop Plants through CRISPR Genome Editing
Rahman, M., Zulfiqar, S., Raza, M. A., Ahmad, N., & Zhang, B. (2022) · Cells · doi:10.3390/cells11223590 · Cited by 75
Holmgaard, A., Askou, A. L., Benckendorff, J. N. E., Thomsen, E. A., Cai, Y., Bek, T., Mikkelsen, J. G., & Corydon, T. J. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.08.016 · Cited by 79
Emerging approaches for restoration of hearing and vision
Kleinlogel, S., Vogl, C., Jeschke, M., Neef, J., & Moser, T. (2020) · Physiological Reviews · doi:10.1152/physrev.00035.2019 · Cited by 91
Liang, Y., Iqbal, Z., Wang, J., Xu, L., Xu, X., Ouyang, K., Zhang, H., Lu, J., Duan, L., & Xia, J. (2022) · Biomaterials Science · doi:10.1039/d2bm00480a · Cited by 72
Akram, F., Sahreen, S., Aamir, F., Haq, I. U., Malik, K. A., Imtiaz, M., Naseem, W., Nasir, N., & Waheed, H. M. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00501-4 · Cited by 83
Li, Z., Wang, J., Xu, J.-P., Wang, J., & Yang, X. F. (2023) · Military Medical Research · doi:10.1186/s40779-023-00447-x · Cited by 93
CRISPR-based genome editing in wheat: a comprehensive review and future prospects
Kumar, R., Kaur, A., Pandey, A., Mamrutha, H. M., & Singh, G. P. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04761-3 · Cited by 70
Evolving AAV-delivered therapeutics towards ultimate cures
He, X., Urip, B. A., Zhang, Z., Ngan, C. C., & Feng, B. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02034-2 · Cited by 72
The use of new CRISPR tools in cardiovascular research and medicine
Nishiga, M., Liu, C., Qi, L. S., & Wu, J. C. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00669-3 · Cited by 73
Recent advances in therapeutic gene-editing technologies
Liu, D., Cao, D., & Han, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.026 · Cited by 75
Evolution of CRISPR/Cas Systems for Precise Genome Editing
Hryhorowicz, M., Lipiński, D., & Zeyland, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814233 · Cited by 74
Tools and targets: the dual role of plant viruses in CRISPR–Cas genome editing
Uranga, M., & Daròs, J. (2023) · The Plant Genome · doi:10.1002/tpg2.20220 · Cited by 68
“Details are as in the legend in Figure 4a. PEG, polyethylene glycol both LbCas12a- and AsCas12a-crRNA RNPs into soybean [Glycine max (L.) Merr.] and tobacco (Nicotiana tabacum L.) protoplasts (Kim et al., 2017b).”
BackgroundGenome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review
Lee, M. H., Shin, J. I., Yang, J. W., Lee, K. H., Cha, D. H., Hong, J. B., Park, Y., Choi, E., Tizaoui, K., Koyanagi, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031337 · Cited by 73
Self-citationRecent Advances in Improving Gene-Editing Specificity through CRISPR–Cas9 Nuclease Engineering
Huang, X., Yang, D., Zhang, J., Xu, J., & Chen, Y. E. (2022) · Cells · doi:10.3390/cells11142186 · Cited by 68
Kim, H. S., Kweon, J., & Kim, Y. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01212-3 · Cited by 90
High-Throughput Approaches to Pinpoint Function within the Noncoding Genome
Montalbano, A., Canver, M. C., & Sanjana, N. E. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.017 · Cited by 76
Creating cell and animal models of human disease by genome editing using CRISPR/Cas9
Zarei, A., Razban, V., Hosseini, S. E., & Tabei, K. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3082 · Cited by 74
Hu, Z., Zhang, C., Wang, S., Gao, S., Wei, J., Li, M., Hou, L., Mao, H., Wei, Y., Qi, T., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab148 · Cited by 73
CRISPR-Cas gene editing technology and its application prospect in medicinal plants
Guo, M., Chen, H., Dong, S., Zhang, Z., & Luo, H. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00584-w · Cited by 68
CRISPR-Cas9 Gene Editing for Fruit and Vegetable Crops: Strategies and Prospects
Wan, L., Wang, Z., Tang, M., Hong, D., Sun, Y., Ren, J. M., Zhang, N., & Zeng, H. (2021) · Horticulturae · doi:10.3390/horticulturae7070193 · Cited by 74
Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 68
Efficient Homology-Directed Repair with Circular Single-Stranded DNA Donors
Iyer, S., Mir, A., Vega‐Badillo, J., Roscoe, B. P., Ibraheim, R., Zhu, L. J., Lee, J., Liu, P., Luk, K., Mintzer, E., et al. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0058 · Cited by 69
Delivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications
Huang, K. L., Zapata, D. A., Tang, Y., Teng, Y., & Li, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121876 · Cited by 66
Wang, J., Zhang, C., & Feng, B. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15039 · Cited by 63
Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9
Li, H., Sheng, C., Liu, H., Wang, S., Zhao, J., Yang, L., Jia, L., Li, P., Wang, L., Xie, J., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02080 · Cited by 60
“AAV9 has the general ability to transduce all major tissues, including muscle (24), retina (25), heart (26), and lung (20) in mice.”
BackgroundTargeting Cancer with CRISPR/Cas9-Based Therapy
Balon, K., Sheriff, A., Jackow, J., & Łaczmański, Ł. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010573 · Cited by 69
Konstantinidis, E., Molisak, A., Perrin, F., Streubel-Gallasch, L., Fayad, S., Kim, D. Y., Petri, K., Aryee, M. J., Aguilar, X., György, B., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.022 · Cited by 66
Self-citationToward the Development of Epigenome Editing-Based Therapeutics: Potentials and Challenges
Ueda, J., Yamazaki, T., & Funakoshi, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054778 · Cited by 63
Crop bioengineering via gene editing: reshaping the future of agriculture
Atia, M. A. M., Jiang, W., Sedeek, K., Butt, H., & Mahfouz, M. M. (2024) · Plant Cell Reports · doi:10.1007/s00299-024-03183-1 · Cited by 71
Rational Design of Mini-Cas9 for Transcriptional Activation
Ma, D., Peng, S., Huang, W., Cai, Z., & Xie, Z. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00404 · Cited by 62
Schmidt, M. J., Gupta, A. K., Bednarski, C., Gehrig-Giannini, S., Richter, F. M., Pitzler, C., Gamalinda, M., Galonska, C., Takeuchi, R., Wang, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24454-5 · Cited by 62
Efficient plant genome engineering using a probiotic sourced CRISPR-Cas9 system
Zhong, Z., Liu, G., Tang, Z., Xiang, S., Yang, L., Huang, L., He, Y., Fan, T., Liu, S., Zheng, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41802-9 · Cited by 59
In vivo base editing extends lifespan of a humanized mouse model of prion disease
An, M., Davis, J. R., Levy, J. M., Serack, F. E., Harvey, J. W., Brauer, P. P., Pirtle, C. P., Berríos, K. N., Newby, G. A., Yeh, W.-H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03466-w · Cited by 64
Jo, D. H., Koo, T., Cho, C. S., Kim, J. H., Kim, J.-S., & Kim, J. H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.009 · Cited by 57
Self-citationAdvances in Genome Editing and Application to the Generation of Genetically Modified Rat Models
Chenouard, V., Remy, S., Tesson, L., Ménoret, S., Ouisse, L.-H., Cherifi, Y., & Anegon, I. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.615491 · Cited by 57
Fei, J., Lou, W. P.-K., Knapp, D., Murawala, P., Gerber, T., Taniguchi, Y., Nowoshilow, S., Khattak, S., & Tanaka, E. M. (2018) · Nature Protocols · doi:10.1038/s41596-018-0071-0 · Cited by 58
Development of Highly Efficient Dual‐AAV Split Adenosine Base Editor for In Vivo Gene Therapy
Chen, Y., Zhi, S., Liu, W., Wen, J., Hu, S., Cao, T., Sun, H., Li, Y., Huang, L. T., Liu, Y., et al. (2020) · Small Methods · doi:10.1002/smtd.202000309 · Cited by 59
CRISPR technologies for the treatment of Duchenne muscular dystrophy
Choi, E., & Koo, T. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.002 · Cited by 59
Self-citationFrom Genome Sequencing to CRISPR-Based Genome Editing for Climate-Resilient Forest Trees
Cao, H. X., Vu, G. T. H., & Gailing, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020966 · Cited by 60
A highly specific CRISPR-Cas12j nuclease enables allele-specific genome editing
Wang, Y., Qi, T., Liu, J., Yang, Y., Wang, Z., Wang, Y., Wang, T., Li, M., Li, M., Lu, D., et al. (2023) · Science Advances · doi:10.1126/sciadv.abo6405 · Cited by 58
Sufyan, M., Daraz, U., Hyder, S., Zulfiqar, U., Iqbal, R., Eldin, S. M., Rafiq, F., Mahmood, N., Shahzad, K., Uzair, M., et al. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01036-w · Cited by 60
Allemailem, K. S., Almatroodi, S. A., Almatroudi, A., Alrumaihi, F., Abdulmonem, W. A., Al‐Megrin, W. A. I., Aljamaan, A. N., Rahmani, A. H., & Khan, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087052 · Cited by 60
Bollen, Y., Post, J. B., Koo, B., & Snippert, H. J. G. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky571 · Cited by 59
Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect
Chuang, Y.-F., Phipps, A. J., Lin, F., Hecht, V. F. G., Hewitt, A. W., Wang, P., & Liu, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03725-2 · Cited by 57
Maybe you can turn me on: CRISPRa-based strategies for therapeutic applications
Bećirović, E. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04175-8 · Cited by 56
Allele-specific editing ameliorates dominant retinitis pigmentosa in a transgenic mouse model
Patrizi, C., Llado-Santaeularia, M., Benati, D., Iodice, C., Marrocco, E., Guarascio, R., Surace, E. M., Cheetham, M. E., Auricchio, A., & Recchia, A. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.01.006 · Cited by 53
In vivo epigenome editing and transcriptional modulation using CRISPR technology
Lau, C., & Suh, Y. (2018) · Transgenic Research · doi:10.1007/s11248-018-0096-8 · Cited by 57
Lee, Y., Mout, R., Luther, D. C., Liu, Y., Castellanos-García, L. J., Burnside, A., Ray, M., Tonga, G. Y., Hardie, J. M., Nagaraj, H., et al. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900041 · Cited by 57
Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome Editing
García, B., Lee, J., Edraki, A., Hidalgo-Reyes, Y., Erwood, S., Mir, A., Trost, C. N., Seroussi, U., Stanley, S. Y., Cohn, R. D., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.017 · Cited by 57
Ryu, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158529 · Cited by 57
CRISPR-Based Genome Editing: Advancements and Opportunities for Rice Improvement
Zegeye, W. A., Tsegaw, M., Zhang, Y., & Cao, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084454 · Cited by 51
Continuous directed evolution of a compact CjCas9 variant with broad PAM compatibility
Schmidheini, L., Mathis, N., Marquart, K. F., Rothgangl, T., Kissling, L., Böck, D., Chanez, C., Wang, J. P., Jínek, M., & Schwank, G. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01427-x · Cited by 52
Allemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Abdulmonem, W. A., Moawad, A. A., Alwanian, W. M., Almansour, N. M., Rahmani, A. H., & Khan, A. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s424872 · Cited by 54
Wang, K., Gong, Q., & Ye, X. (2019) · Theoretical and Applied Genetics · doi:10.1007/s00122-019-03464-4 · Cited by 52
AcrIIA5 Inhibits a Broad Range of Cas9 Orthologs by Preventing DNA Target Cleavage
Song, G., Zhang, F., Zhang, X., Gao, X., Zhu, X., Fan, D., & Tian, Y. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.078 · Cited by 54
Catalytic-state structure and engineering of Streptococcus thermophilus Cas9
Zhang, Y., Zhang, H., Xu, X., Wang, Y., Chen, W., Wang, Y., Wu, Z., Tang, N., Wang, Y., Zhao, S., et al. (2020) · Nature Catalysis · doi:10.1038/s41929-020-00506-9 · Cited by 51
Kantor, B., O’Donovan, B., Rittiner, J. E., Hodgson, D., Lindner, N., Guerrero, S., Dong, W., Zhang, A., & Chiba‐Falek, O. (2024) · Nature Communications · doi:10.1038/s41467-024-50515-6 · Cited by 52
Raikwar, S. P., Kikkeri, N. S., Sakuru, R. C., Saeed, D., Zahoor, H., Premkumar, K., Mentor, S., Thangavel, R., Dubova, I., Ahmed, M. E., et al. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09849-y · Cited by 54
Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases
Yu, W., & Wu, Z. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.011 · Cited by 50
Engineering of efficiency-enhanced Cas9 and base editors with improved gene therapy efficacies
Yin, S., Zhang, M., Liu, Y., Sun, X., Guan, Y., Chen, X., Yang, L., Huo, Y., Yang, J., Zhang, X., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.014 · Cited by 50
Programmable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech
Saha, S. K., Saikot, F. K., Rahman, M. S., Jamal, M. A. H. M., Rahman, S. M. K., Islam, S. M. R., & Kim, K. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.016 · Cited by 51
Self-citationStructural basis for the promiscuous PAM recognition by Corynebacterium diphtheriae Cas9
Hirano, S., Abudayyeh, O. O., Gootenberg, J. S., Horii, T., Ishitani, R., Hatada, I., Zhang, F., Nishimasu, H., & Nureki, O. (2019) · Nature Communications · doi:10.1038/s41467-019-09741-6 · Cited by 49
CRISPR/Cas System for Genome Editing: Progress and Prospects as a Therapeutic Tool
Sahel, D. K., Mittal, A., & Chitkara, D. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.257287 · Cited by 49
CRISPR-based strategies for targeted transgene knock-in and gene correction
Lau, C., Tin, C., & Suh, Y. (2020) · Faculty Reviews · doi:10.12703/r/9-20 · Cited by 51
Guide-free Cas9 from pathogenic Campylobacter jejuni bacteria causes severe damage to DNA
Saha, C. K., Mohanraju, P., Stubbs, A., Dugar, G., Hoogstrate, Y., Kremers, G., van Cappellen, W. A., Horst-Kreft, D., Laffeber, C., Lebbink, J. H. G., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz4849 · Cited by 48
Evaluation of Engineered CRISPR-Cas-Mediated Systems for Site-Specific RNA Editing
Marina, R. J., Brannan, K. W., Dong, K. D., Yee, B. A., & Yeo, G. W.-M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108350 · Cited by 47
Zhang, X., Lv, S., Luo, Z., Hu, Y., Peng, X., Lv, J., Zhao, S., Feng, J., Huang, G., Wan, Q.-L., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab174 · Cited by 50
FrCas9 is a CRISPR/Cas9 system with high editing efficiency and fidelity
Cui, Z., Tian, R., Huang, Z., Jin, Z., Li, L., Liu, J., Huang, Z., Xie, H., Liu, D., Mo, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29089-8 · Cited by 46
Metadata
- Authors
- Kim, E., Koo, T., Park, S. W., Kim, D., Kim, K., Cho, H.-Y., Song, D. W., Lee, K. J., Jung, M. H., Kim, S., Kim, J. H., Kim, J. H., & Kim, J.-S.
- Affiliations
- Institute for Basic Science (KR)
- Seoul National University (KR)
- ToolGen (South Korea) (KR)
- Corresponding author
- Kim, Jeong Hun
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-21
- Volume
- 8
- Issue
- 1
- Pages
- 14500-14500
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5473640
- OpenAlex
- W2590764628
- Cited by
- 715
- References
- 38
- Citations by year
- 2026: 24 · 2025: 68 · 2024: 68 · 2023: 81 · 2022: 114 · 2021: 94 · 2020: 87 · 2019: 77 · 2018: 66 · 2017: 36
- FWCI
- 29.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- National Research Foundation (NRF-2015M3A9E6028949)
- Ministry of Science, ICT and Future Planning (NRF-2015M3A9E6028949, IBS-R021-D1, 2015M3A9E6028949)
- Korea Health Industry Development Institute (HI16C0426)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- in vivo gene editing, adeno-associated virus vectors, single guide RNA, protospacer adjacent motif, retinal pigment epithelium, choroidal neovascularization, age-related macular degeneration, VEGF-A, HIF1A, targeted mutagenesis
- MeSH terms
- Gene Editing, Dependovirus, Animals, Bacterial Proteins, Cells, Cultured, Endonucleases, Humans, Male, Mice, Inbred C57BL, Campylobacter jejuni, Choroidal Neovascularization, Vascular Endothelial Growth Factor A, Retinal Pigment Epithelium, HEK293 Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.